{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T19:05:54Z","timestamp":1661195154399},"reference-count":112,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.clindermatol.2011.08.002","type":"journal-article","created":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T05:37:06Z","timestamp":1319089026000},"page":"614-621","source":"Crossref","is-referenced-by-count":2,"title":["Iatrogenic effects of biologics for psoriasis"],"prefix":"10.1016","volume":"29","author":[{"given":"Mary L.","family":"Stevenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2011.08.002_bb0005","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0010","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1067\/mjd.2001.117725","article-title":"Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy","volume":"45","author":"Smith","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0015","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archderm.141.7.861","article-title":"No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years","volume":"141","author":"Lebwohl","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0025","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0035","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isomaki","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0045","first-page":"809","article-title":"Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee","volume":"18","author":"Matteson","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0055","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0060","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0065","series-title":"FDA Meeting March 2003: update on the safety of new drugs for rheumatoid arthritis","author":"American College of Rheumatology","year":"2003"},{"issue":"5 Suppl 31","key":"10.1016\/j.clindermatol.2011.08.002_bb0070","first-page":"S203","article-title":"The safety of biologic agents in early rheumatoid arthritis","volume":"21","author":"Kavanaugh","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00002018-200427050-00003","article-title":"Safety of tumour necrosis factor-alpha antagonists","volume":"27","author":"Khanna","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0080","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0085","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0090","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00002018-200831050-00013","article-title":"TNF-alpha inhibitors and leukaemia: international pharmacovigilance reports","volume":"31","author":"Meyboom","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0100","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0b013e3282f7c706","article-title":"Malignancy and biologic therapy in rheumatoid arthritis","volume":"20","author":"Askling","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0115","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1067\/S0190-9622(03)00811-9","article-title":"Etanercept and squamous cell carcinoma","volume":"49","author":"Burge","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0120","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jaad.2004.07.031","article-title":"Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy","volume":"51","author":"Fryrear","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0125","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1365-2133.2007.08182.x","article-title":"The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis","volume":"157","author":"Ly","year":"2007","journal-title":"Br J Dermatol"},{"issue":"5 Suppl","key":"10.1016\/j.clindermatol.2011.08.002_bb0130","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2006.12.024","article-title":"Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies","volume":"56","author":"Fulchiero","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaad.2006.06.032","article-title":"Acute myelogenous leukemia in a patient receiving etanercept for psoriasis","volume":"56","author":"Bachmeyer","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0140","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ajh.20926","article-title":"TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature","volume":"82","author":"Nair","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1746-1596-3-13","article-title":"A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists","volume":"3","author":"Hurley","year":"2008","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2133.2003.05384.x","article-title":"CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab","volume":"149","author":"Mahe","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0155","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMc0800250","article-title":"Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy","volume":"359","author":"Lees","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0165","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0170","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/art.20973","article-title":"Development of fatal tuberculosis in a patient with rheumatoid arthritis after three years of treatment with infliximab: comment on the article by Wolfe et al","volume":"52","author":"Molenaar","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0175","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","article-title":"TNF-blocking agents and tuberculosis: new drugs illuminate an old topic","volume":"44","author":"Keane","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0180","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","article-title":"Immunology of tuberculosis","volume":"19","author":"Flynn","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0185","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0190","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/424455","article-title":"Granulomatous infections due to tumor necrosis factor blockade: correction","volume":"39","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0195","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0200","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clindermatol.2011.08.002_bb0210","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2009.123885","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009","volume":"69","author":"Furst","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0215","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0220","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0225","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0230","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard.62.1.81","article-title":"Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab","volume":"62","author":"Matzkies","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0240","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0245","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0250","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/art.10374","article-title":"Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases","volume":"46","author":"Gluck","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0255","first-page":"1100","article-title":"Letter in reply to Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Keenan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0260","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/377235","article-title":"Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists","volume":"37","author":"Gottlieb","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0265","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00277-003-0705-2","article-title":"Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT)","volume":"82","author":"Gonzalez-Vicent","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0270","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.inf.0000055092.90609.e5","article-title":"Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept","volume":"22","author":"Elwood","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0275","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9394(02)01499-X","article-title":"Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy","volume":"134","author":"Cursiefen","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0280","first-page":"1561","article-title":"Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab","volume":"29","author":"True","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0285","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0290","first-page":"421","article-title":"Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis","volume":"35","author":"Cansu","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0295","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/BOR.0b013e328338f6df","article-title":"B, Cs of viral hepatitis in the biologic era","volume":"22","author":"Ferri","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0305","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaad.2009.07.010","article-title":"Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data","volume":"62","author":"Paradisi","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0310","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0315","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0320","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0325","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0330","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-006-0215-3","article-title":"The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists","volume":"27","author":"Cole","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0335","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0340","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0345","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1529-8019.2010.01307.x","article-title":"Psoriasis and the metabolic syndrome","volume":"23","author":"Alsufyani","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0350","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/art.20164","article-title":"Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?","volume":"50","author":"Khanna","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0355","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1388-9842(02)00121-6","article-title":"Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0360","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/1529-0131(200011)43:11<2381::AID-ANR1>3.0.CO;2-M","article-title":"Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies","volume":"43","author":"Pisetsky","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0365","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0370","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/1529-0131(200107)44:7<1721::AID-ART302>3.0.CO;2-J","article-title":"Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky","volume":"44","author":"Aringer","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0375","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0380","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14740338.7.4.411","article-title":"Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus","volume":"7","author":"Aringer","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0385","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/rheumatology\/kep270","article-title":"Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients","volume":"48","author":"Aringer","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0390","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0395","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0400","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/art.27687","article-title":"A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab","volume":"62","author":"Kumar","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0405","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0410","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0415","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0420","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0425","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2133.2004.06107.x","article-title":"Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases","volume":"151","author":"Dereure","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0430","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0435","first-page":"1411","article-title":"Anti-tumor necrosis factor-alpha-induced psoriasis","volume":"33","author":"Sari","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0440","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.rhu.0000240045.16855.39","article-title":"The appearance of pustular psoriasis during antitumor necrosis factor therapy","volume":"12","author":"Goncalves","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0445","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series","volume":"34","author":"Cohen","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0450","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0455","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archderm.143.2.270","article-title":"Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases","volume":"143","author":"Ubriani","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0460","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1365-2133.2005.06977.x","article-title":"Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?","volume":"153","author":"Michaelsson","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0465","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0470","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0475","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0480","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0485","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1126\/science.280.5368.1435","article-title":"Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients","volume":"280","author":"de Jong","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0490","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.280.5368.1432","article-title":"Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency","volume":"280","author":"Altare","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0495","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1172\/JCI4950","article-title":"Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection","volume":"102","author":"Altare","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0500","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1086\/425021","article-title":"Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans","volume":"190","author":"MacLennan","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0505","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.4049\/jimmunol.167.9.5304","article-title":"IL-12p40-dependent agonistic effects on the development of protective innate and adaptive immunity against Salmonella enteritidis","volume":"167","author":"Lehmann","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0510","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.4049\/jimmunol.181.11.7891","article-title":"Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17","volume":"181","author":"Schulz","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0515","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","article-title":"Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis","volume":"122","author":"Capon","year":"2007","journal-title":"Hum Genet"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0520","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.178.1.211","article-title":"Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses","volume":"178","author":"Miller","year":"1993","journal-title":"J Exp Med"},{"issue":"2 Suppl 2","key":"10.1016\/j.clindermatol.2011.08.002_bb0525","first-page":"AB191","article-title":"Assesment and Tracking of long-term alefacept safety (ATLAS): analysis of data from approximately 1,200 patients","volume":"56","author":"Krell","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0530","unstructured":"Amevive\u2122 (alefacept) prescribing information. Deerfield, IL: Astellas Pharma US, Inc; 2009."},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0535","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0540","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mjd.2002.127247","article-title":"A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis","volume":"47","author":"Krueger","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0545","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0550","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.clinthera.2005.12.007","article-title":"An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy","volume":"27","author":"Goffe","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0555","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.sder.2010.03.002","article-title":"Alefacept for psoriasis","volume":"29","author":"Heffernan","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2011.08.002_bb0560","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for psoriasis and the risk of malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11002069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11002069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T09:24:22Z","timestamp":1543483462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X11002069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0738081X11002069"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2011.08.002","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}